Chapel Hill, NC, United States
Chapel Hill, NC, United States

Time filter

Source Type

News Article | April 20, 2017
Site: marketersmedia.com

— The antibacterial drug market covers the drugs used in the prophylaxis and treatment of bacterial infections. With a growing global concern over antimicrobial resistance and its progressive growth, there is a pronounced need for innovation within this market. Browse 27 Tables and 76 Figures, 10 Companies Spread across 177 pages is available @ http://www.reportsnreports.com/contacts/discount.aspx?name=956399 . Company Analysis Profiled are Pfizer, GlaxoSmithKline, Merck & Co, Allergan, Cempra, Insmed, Otsuka, Roche, Bayer and AstraZeneca. The report, Global Antibacterial Drugs Market to 2022 - Vaccines Retain Market Prominence While Pipeline Offers Innovative Approaches to Tackling Antimicrobial Resistance, states that emerging companies and the approvals of new products will drive this growth, along with the continued success of the established marketed products Infanrix, which vaccinates against diphtheria, tetanus and pertussis, and Augmentin, which is amoxicillin sodium and clavulanate potassium. The antibacterial market is currently dominated by vaccines, in particular those for the prevention of pneumococcal infections, diphtheria, tetanus and pertussis. However, recent years have seen key additions in the form of therapies for antibiotic-resistant bacteria, including strains with multi-drug resistance. The number of such products is expected to increase drastically between 2016 and 2022. Drugs for the prevention of bacterial infections are typically vaccines, which help to train the body's immune system to fight off specific infections, and can therefore help to prevent infections of certain bacterial strains. However, several prophylactic monoclonal antibodies are also currently in development. Drugs for the treatment of bacterial infections are slightly more varied. Most common are beta-lactam antibiotics, which include the very widely prescribed penicillin. However, bacteria have developed resistance to penicillin by producing beta-lactamase enzymes that break open the beta-lactam ring found in these antibiotics, rendering them ineffective. As a result modern beta-lactams are frequently combination drugs of a beta-lactam and a beta-lactamase inhibitor. Order a Copy of Report @ http://www.reportsnreports.com/purchase.aspx?name=956399 .In addition to beta-lactams there are several other classes of drugs used to treat bacterial infections. These include fluoroquinolones, which inhibit DNA gyrase and/or topoisomerase IV; and protein synthesis inhibitors, which have applications within the treatment of bacteria that are resistant to beta-lactam antibiotics. However, bacterial resistance has also developed against these drugs, and as such there is a gap in the market for a new generation of drugs that are effective against drug-resistant bacteria. Antibiotic resistance has caused a surge in the development of antibiotics: • How big is the antibiotic pipeline? • How are companies attempting to overcome antibiotic resistance? The Antibacterial Drug Market is forecast to rise from around $27.1 billion in 2015 to $35.6 billion in 2022: • How much will the approval of new products and the patent expiries of existing ones contribute to this market growth? • Will vaccines continue to drive market revenue? The pipeline contains a range of molecular targets: • Which molecular targets are most popular in the current pipeline? • How many late-stage products are active against drug-resistant bacteria? • What are the commercial prospects for the most promising late-stage pipeline products? Big Pharma maintains a strong presence within the antibacterial drug market: • Which of the leading companies are expected to have the highest share of the market by 2022? • Which of the leading pharmaceutical companies are expected to bring new products to market during the forecast period? • Which companies rely heavily of revenues derived from antibacterial drugs? About Us ReportsnReports.com is single source for all market research needs. Our database includes 500,000+ market research reports from over 95 leading global publishers & in-depth market research studies of over 5000 micro markets. For more information, please visit http://www.reportsnreports.com/reports/956399-global-antibacterial-drugs-market-to-2022-vaccines-retain-market-prominence-while-pipeline-offers-innovative-approaches-to-tackling-antimicrobial-resistance.html


The invention described herein pertains to processes for the preparation of macrolide antibacterial agents. In particular, the invention pertains to processes for preparing macrolides and ketolides from erythromycin A.


Patent
Cempra | Date: 2014-06-19

Described herein are macrolide and ketolide antibiotics and pharmaceutical compositions, methods, and uses thereof for treating gastrointestinal diseases.


Compounds, compositions, methods, and uses are described herein for the treatment of respiratory diseases, including cystic fibrosis. Inhalation formulations of macrolide antibiotics are also described herein. The treatment of bacterial infections continues to be an important endeavor of pharmaceutical research and development. The specter of bacterial resistance to currently available antibiotics is ever-present, and accordingly, new and improved compounds, pharmaceuticals formulations, treatment methods, and treatment protocols are needed.


The invention described herein relates to processes for preparing ketolide antibacterial agents. In particular, the invention relates to intermediates and processes for preparing ketolides that include a 1,2,3-triazole substituted side chain.


Patent
Cempra | Date: 2013-05-22

New crystalline forms of macrolide compounds, and pharmaceutical compositions thereof, are described herein. In addition, processes for preparing the crystalline forms are described herein.


Patent
Cempra | Date: 2015-09-21

New crystalline forms of macrolide compounds, and pharmaceutical compositions thereof, are described herein. In addition, processes for preparing the crystalline forms are described herein.


Described herein are macrolide and ketolide antibiotics and pharmaceutical compositions, methods, and uses thereof for treating diseases caused at least in party by resistant bacteria.


Patent
Cempra | Date: 2015-05-29

Use of macrolide and ketolide antibiotics for the treatment of acute exposure and diseases caused by biodefense pathogens is described.


Patent
Cempra | Date: 2016-06-15

Use of macrolide and ketolide antibiotics for the treatment of acute exposure and diseases caused by biodefence pathogens is described.

Loading Cempra collaborators
Loading Cempra collaborators